Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.60 Analyst target: $20.00 Upside: 1150.00%
InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.
See the full interactive analysis & chart →Informational only — not investment advice.